Shire PLC (SHPG.OQ)

SHPG.OQ on NASDAQ Stock Exchange Global Select Market

260.15USD
29 May 2015
Change (% chg)

$0.33 (+0.13%)
Prev Close
$259.82
Open
$261.17
Day's High
$261.55
Day's Low
$258.24
Volume
142,596
Avg. Vol
142,046
52-wk High
$264.94
52-wk Low
$156.34

SHPG.OQ

Chart for SHPG.OQ

About

Shire Plc is a specialty biopharmaceutical company that focuses on developing and marketing innovative specialty medicines that address unmet patient needs. The Company’s products included VYVANSE/VENVANSE (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release... (more)

Overall

Beta: 0.65
Market Cap(Mil.): $51,056.01
Shares Outstanding(Mil.): 197.22
Dividend: 0.57
Yield (%): 0.26

Financials

  SHPG.OQ Industry Sector
P/E (TTM): 14.86 36.11 38.09
EPS (TTM): 17.50 -- --
ROI: 32.47 16.12 15.45
ROE: 47.07 16.91 16.49
Search Stocks

UPDATE 1-Binge eating drug helps Shire deliver first-quarter earnings beat

* Shares up 2.8 percent (Adds CEO comments, analyst reaction, shares)

30 Apr 2015

BRIEF-Shire names Jeff Poulton as CFO

* Jeff has served as interim cfo since december 2014, while overseeing investor relations Source text for Eikon: Further company coverage:

30 Apr 2015

UK's FTSE races to new record high as Shire shines

LONDON, April 10 - Britain's top equity index sprinted to new record highs on Friday, as real-estate stocks extended gains from a rebound in property prices and drugmaker Shire got a lift from a positive product review.

10 Apr 2015

Britain's FTSE nears record high as Shire shines

LONDON, April 10 - Britain's top equity index advanced on Friday, nearing record highs, as real-estate stocks extended gains from a rebound in property prices and drugmaker Shire got a lift from a positive product review.

10 Apr 2015

Britain's FTSE nears record high as real estate prospers

LONDON, April 10 - Britain's top equity index advanced on Friday, nearing record highs, as real-estate stocks extended gains from a rebound in property prices and drugmaker Shire got a lift from a positive product review.

10 Apr 2015

Britain's FTSE nears all-time high as real estate prospers

LONDON, April 10 - Top UK shares rose on Friday, nearing all-time highs as real-estate stocks extended gains from a rebound in property prices and drugmaker Shire got a lift from a priority drug review in the United States.

10 Apr 2015

BRIEF-Shire says U.S. FDA grants priority review to lifitegrast NDA

* FDA is expected to provide a decision on October 25, 2015, based on prescription drug user fee act v action date Source text for Eikon: Further company coverage: (Bengaluru Newsroom; +44 207 542 1810)

09 Apr 2015

BRIEF-Shire's Alagille syndrome drug does not meet study goal

* Topline results from first of three placebo-controlled phase 2 studies of shp625 (lum001) in children with alagille syndrome

09 Apr 2015

Shire agrees regulatory path for ADHD drug for adults

LONDON, April 7 - Pharmaceutical firm Shire said on Tuesday it had agreed with U.S. regulators the steps it would take to submit a candidate drug to treat hyperactivity in adults for clearance.

07 Apr 2015

AbbVie CEO defends Pharmacyclics deal to skeptical investors

NEW YORK - AbbVie Inc chief Richard Gonzalez fought two other drugmakers to "the bitter end" to buy Pharmacyclics Inc for its hot-selling Imbruvica cancer drug, but may have a harder time convincing investors it is worth $21 billion.

05 Mar 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Sadif Analytics Prime
$25.00
Provider: Pechala's Reports
$1,000.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks